The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.
November 26th 2024
The investigators of this study noted an association between obesity and conditions such as rosacea, psoriasis, and lichen simplex chronicus.
November 22nd 2024
November 19th 2024
Possibility for Personalized Psoriasis Treatment on the Horizon
Psoriasis, plaguing patients with its seemingly incurable symptoms, may have met its match. Skylit Medical, a startup in San Diego, is developing a phototherapy device to use as treatment for psoriasis as well as eczema and vitiligo.
Facial Rash in an Elderly Woman
September 2nd 2014This 70-year-old woman was referred for this waxing and waning erythematous facial rash of two years duration. She has tried topical metronidazole and clindamycin without improvement. Her past medical history is significant for hypertension and hypothyroidism, otherwise she is in good health and a review of systems is negative except for the itching facial rash.
Widespread Use of Personal Electronics Drives Increase in Nickel Allergies
With more people than ever using cell phones, tablets, and other personal technological devices, dermatologists have voiced concerns over the increase in cases of nickel allergies. Nickel, one of the most prevalent allergens in the United States, can be found within most handheld electronic devices and jewelry.
The National Psoriasis Foundation Announces Ambitious New Programs and Initiatives
August 21st 2014The National Psoriasis Foundation (NPF) recently announced a number of new programs and a five-year strategic mission for the organization with initiatives that are designed to increase research and uncover new treatments for all forms of psoriasis and psoriatic disease.
Researchers Discover Molecular Changes Responsible for Skin Discoloration in Psoriasis
Many control psoriasis-ridden skin only to find traces of discolored patches in its wake. A study by the Milstein Medical Research Program at The Rockefeller University has uncovered the correlation between skin discoloration and psoriasis, providing opportunities of treatment for pigmentation changes within eczema and acne as well.
Hyperpigmented Back Lesion in a Young Woman
July 22nd 2014This 28-year-old woman presented with a large hyperpigmented patch on the right side of her upper back. Although the lesion developed over the past 2 years, it has been "sinking in" over the past 2 weeks. The patient denies any trauma, pain, discomfort, or pruritis, as well as any family history of cancers, lymphoma, or autoimmune disease. However, she has a history of gastroesophageal reflux disease and onychomycosis, and her grandfather has a similar lesion.
Steps to Minimize Serious Risks of Biologic Treatment for Autoimmune Disease
July 19th 2014Although tumor necrosis factor inhibitors have dramatically improved management strategies for autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease, the biologic agents also pose a number of significant side effects that physicians must consider.
Topical Treatments Show Some Benefit for Plaque Psoriasis Patients
As research continues to be done to find the most efficient treatment for patients with plaque psoriasis a study was recently published looking at how the inclusion of topical corticosteroids can benefit the care provided.
Recognition of Methotrexate Toxicity Key for Patient Treatment
For more than 70 years methotrexate has been a popular tool in the prescription toolkit of doctors around the world. However, a recent case report by a team from the United Kingdom showed how important it is for prescribing doctors to also keep a close eye on some of the well-known adverse events associated with the medication.
Weight Loss Improves Disease Management in Patients with Psoriatic Arthritis
July 1st 2014Study results show that obese patients with psoriatic arthritis who were treated with tumor necrosis factor-alpha blockers who also lost at least 5 percent of their bodyweight from baseline were much more likely to achieve minimal disease activity.